In the fall of 1999, the drug giant SmithKline Beecham secretly began a study to find out if its diabetes medicine, Avandia, was safer for the heart than a competing pill, Actos, made by Takeda. 

 

Avandia’s success was crucial to SmithKline, whose labs were otherwise all but barren of new products.